Short Bowel Syndrome Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Short Bowel Syndrome Market is Segmented by Drug Class (GLP-2, Growth Hormone, Glutamine, and Others), Distribution Channel and Geography

Market Snapshot

 malabsorption syndrome market growth
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >29.8 %
malabsorption syndrome market share

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Short Bowel Syndrome (SBS) Market studied was anticipated to grow with a CAGR of nearly 29.8%, during the forecast period. The major factors attributing to the growth of the SBS market are rise in global prevalence of GI disorders like volvulus, Inflammatory bowel disease (IBD), in particular, Crohn’s disease (CD), which predisposes patients to development of SBS and mesenteric ischemia are the most common causes for SBS among all the age groups which demand the necessity of the treatment. 

Additionally, the increased awareness programs led by several associations like the Association of gastrointestinal motility, Oley Foundation and the SBS Cure Project coupled with rising in the government health care expenditure are likely to drive the market growth over the forecast period.

Scope of the Report

As per the scope of the report, short bowel syndrome (SBS) is a metabolic disorder that occurs due to the malfunctioning or removal of the small intestine through surgery due to digestive illness. The consequences may be malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.

By Drug Class
Growth Hormone
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Rest of the World

Report scope can be customized per your requirements. Click here.

Key Market Trends

GLP-2 Drug Therapy by Drug Class is Expected to Hold the Largest Market Share During the Forecast Period

The GLP-2 drug treatment accounts for the major market share throughout the forecast period. The dominance is due to the only products available for treatment with the brand names Gattex and Revestive, introduced by Takeda which were approved for sales in both the US and Europe respectively. Also, the patent exclusivity of GLP-2 drug is anticipated to contribute to its significant share in the revenue of the global short bowel syndrome market. 

By distribution channels, hospital pharmacies are accounted for the highest market share due to the rapid implementation of therapy due to a huge patient pool. Also, the preference by the patients due to unaffordability and higher expensive parenteral nutrition along with prescription products contribute to a major share in the global short bowel syndrome market.

malabsorption syndrome market size

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall Short Bowel Syndrome Market throughout the forecast period. This dominance is mainly due to the revenue generated by the Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S. Also, rise in the sedentary lifestyle that led no time to focus on nutritious and healthy food with increased consumption of unhealthy and junk food, resultant intestinal disorders are a major factor that drives the market growth in the region.

The Asia Pacific is anticipated to grow at the fastest rate during the forecast period due to the huge patient pool in China and India, and the uncontrolled consumption of antibiotics in India. Also, the research activities and investments on R&D in the region are estimated to fuel the growth of the SBS market in the Asia Pacific and attribute to a significant share in global market.

malabsorption syndrome market trends

Competitive Landscape

The global short bowel syndrome market is moderately competitive and consists of several prominent industry players. Some prominent players are making partnerships and acquiring the blockbuster products in the market, other companies and expanding their market position globally. For instance, Takeda acquired the Shire, to expanding its geographic footprint and to be a leader in providing targeted treatments in gastroenterology, the leading companies in gastroenterology (GI) and neuroscience. While other key players are focusing on distributing and manufacturing of over-the-counter dietary supplements. Whereas, some companies such as Naia Pharmaceuticals SBS, Micelle BioPharma, Inc. are having new products in their pipeline. Some of the companies which are currently dominating the market are TAKEDA Inc, Naia Pharmaceuticals Inc, VectivBio AG, OxThera Inc, and Nutrinia Inc.

Recent Developments

Takeda Pharmaceuticals, on May 2019, announced that the US FDA approved extending the indication of GATTEX (teduglutide) for injection to pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding (parenteral support).

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increased Prevalence of Short Bowel Syndrome and Awareness Programs by Non-Profit Organizations

      2. 4.2.2 Rising Efforts in the Launch of Effective Treatments and Awareness Programs by Non-Profit Organizations

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Availability of the Approved Drugs in Developing Countries

      2. 4.3.2 Lethal Adverse Complications like Colonic Cancer, Polyps along with Common Side Effects Associated with the Medication

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Drug Class

      1. 5.1.1 GLP-2

      2. 5.1.2 Growth Hormone

      3. 5.1.3 Glutamine

      4. 5.1.4 Others

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Rest of the World


    1. 6.1 Company Profiles

      1. 6.1.1 Takeda Pharmaceutical Company Limited

      2. 6.1.2 OxThera Inc.

      3. 6.1.3 VectivBio AG

      4. 6.1.4 Nutrinia

      5. 6.1.5 Merck KGaA

      6. 6.1.6 Pfizer Inc

      7. 6.1.7 Ardelyx

      8. 6.1.8 Zealand Pharma

      9. 6.1.9 Nestlé S.A.,

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Short Bowel Syndrome Market market is studied from 2018 - 2026.

The Short Bowel Syndrome Market is growing at a CAGR of >29.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

TAKEDA Inc, Nutrinia, OxThera, VectivBio AG, Ardelyx are the major companies operating in Short Bowel Syndrome Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!